| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
24,727 |
196,382 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,194,336 |
$28,520,846 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
20 |
73 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-05-16 |
4 |
AS |
$145.20 |
$14,520 |
D/D |
(100) |
17,753 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2016-05-16 |
4 |
S |
$145.20 |
$93,509 |
D/D |
(644) |
4,221 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2016-05-16 |
4 |
S |
$145.20 |
$101,204 |
D/D |
(697) |
5,396 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2016-05-12 |
4 |
D |
$145.23 |
$118,362 |
D/D |
(815) |
33,809 |
|
- |
|
| Smith Karen L. |
Global Head of R&D and CMO |
• – – |
2016-05-11 |
4 |
D |
$148.76 |
$95,355 |
D/D |
(641) |
12,399 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-05-05 |
4 |
D |
$145.75 |
$136,859 |
D/D |
(939) |
17,853 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2016-05-03 |
4 |
D |
$152.47 |
$179,457 |
D/D |
(1,177) |
34,624 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-04-25 |
4 |
AS |
$160.00 |
$96,640 |
D/D |
(604) |
18,059 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-04-15 |
4 |
AS |
$145.79 |
$14,579 |
D/D |
(100) |
18,792 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-04-13 |
4 |
AS |
$150.00 |
$751,050 |
D/D |
(5,007) |
18,663 |
|
- |
|
| Smith Karen L. |
Global Head of R&D and CMO |
• – – |
2016-04-13 |
4 |
D |
$147.34 |
$15,176 |
D/D |
(103) |
13,040 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-04-12 |
4 |
AS |
$136.98 |
$547,920 |
D/D |
(4,000) |
60,470 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-04-07 |
4 |
AS |
$140.90 |
$304,485 |
D/D |
(2,161) |
23,670 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-03-15 |
4 |
AS |
$129.17 |
$12,917 |
D/D |
(100) |
18,892 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-03-08 |
4 |
AS |
$126.04 |
$315,100 |
D/D |
(2,500) |
300,066 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-03-07 |
4 |
D |
$127.84 |
$198,152 |
D/D |
(1,550) |
64,470 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-03-07 |
4 |
D |
$127.84 |
$71,974 |
D/D |
(563) |
25,831 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2016-03-07 |
4 |
D |
$127.84 |
$104,573 |
D/D |
(818) |
21,151 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2016-03-07 |
4 |
D |
$127.84 |
$234,203 |
D/D |
(1,832) |
41,141 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-03-07 |
4 |
D |
$127.84 |
$574,385 |
D/D |
(4,493) |
302,566 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2016-02-29 |
4 |
D |
$121.58 |
$392,703 |
D/D |
(3,230) |
307,059 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2016-02-29 |
4 |
S |
$123.47 |
$43,712 |
D/D |
(354) |
15,100 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2016-02-29 |
4 |
D |
$121.58 |
$42,310 |
D/D |
(348) |
26,394 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2016-02-29 |
4 |
D |
$121.58 |
$114,164 |
D/D |
(939) |
66,020 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2016-02-29 |
4 |
D |
$121.58 |
$51,307 |
D/D |
(422) |
35,801 |
|
- |
|
1250 Records found
|
|
Page 26 of 50 |
|
|
0.37 (0.34%) 
